|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Importantly, we show that Dub3 overexpression is responsible for an abnormally high level of Cdc25A in a subset of human breast cancers.
|
20228808 |
2010 |
|
Mammary Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Moreover, Dub3 knockdown significantly retarded the growth of breast tumour xenografts in nude mice.
|
20228808 |
2010 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The constitutive expression of USP17 and its substrate SDS3 was involved in the inhibition of anchorage-independent tumor growth and blocks cell proliferation, leading to apoptosis in cervical carcinoma cells.
|
21239494 |
2011 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These data support the possibility that SDS3, being a substrate of USP17, may play an important role in developing a novel therapeutic means to inhibit specific HDAC activities in cancer.
|
21239494 |
2011 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These data support the possibility that SDS3, being a substrate of USP17, may play an important role in developing a novel therapeutic means to inhibit specific HDAC activities in cancer.
|
21239494 |
2011 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
We wished to investigate whether the HABMs of USP17 were responsible for tumor suppression activity.
|
22662218 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Patients with USP17 positive tumors had significantly reduced recurrence-free survival than patients with USP17 negative tumors.
|
24123619 |
2013 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, USP17 was more highly expressed in patients with recurrence of disease at distant sites, suggesting that USP17 levels may correlate with NSCLC distant metastases.
|
24123619 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, USP17 was more highly expressed in patients with recurrence of disease at distant sites, suggesting that USP17 levels may correlate with NSCLC distant metastases.
|
24123619 |
2013 |
|
Secondary Neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Moreover, USP17 was more highly expressed in patients with recurrence of disease at distant sites, suggesting that USP17 levels may correlate with NSCLC distant metastases.
|
24123619 |
2013 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP17 was overexpressed in both squamous and adenocarcinoma NSCLC tissue.
|
24123619 |
2013 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, these findings establish USP17 as a potentially valuable novel biomarker for metastatic lung cancer.
|
24123619 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, USP17 expression was up-regulated in CD4(+) T cells from systemic lupus erythematosus patients.
|
25070893 |
2014 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
|
26378038 |
2015 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Dub3 is a deubiquitinating enzyme.It is highly expressed in tumor-derived cell lines and has an established role in tumor proliferation.
|
25776484 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
|
26378038 |
2015 |
|
Tumor Progression
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
|
25776484 |
2015 |
|
ovarian neoplasm
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Multivariate survival analysis indicated that Dub3 expression was an independent prognostic indicator of the survival of patients with ovarian cancer.
|
25776484 |
2015 |
|
Malignant neoplasm of ovary
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Multivariate survival analysis indicated that Dub3 expression was an independent prognostic indicator of the survival of patients with ovarian cancer.
|
25776484 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Multivariate survival analysis indicated that Dub3 expression was an independent prognostic indicator of the survival of patients with ovarian cancer.
|
25776484 |
2015 |
|
Cystadenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of Dub3 expression were examined by immunohistochemical analysis in 13.3% of cystadenomas, in 30.0% of borderline tumors, and in 58.9% of ovarian carcinomas, respectively.
|
25776484 |
2015 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
|
25776484 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dub3 expression was significantly associated with lymph node metastasis and clinical staging (P<0.05).
|
25776484 |
2015 |
|
Glucocorticoid Receptor Deficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Small molecules which can specifically induce the expression of USP17 might be useful in reversing glucocorticoid resistance.
|
26617781 |
2015 |
|
Tumor Progression
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Subsequent in vivo experiments showed that overexpression of USP17 suppressed tumor progression in an orthotopic glioma models.
|
26777424 |
2016 |